nVerses Capital’s Kiniksa Pharmaceuticals KNSA Stock Holding History

nVerses Capital’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-3,200	Closed	-$80K	–	453
2024 Q3	$80K	Buy	+3,200	New	+$78K	0.04%	521

Other funds holding KNSA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

nVerses Capital's KNSA Position: Q4 2024 in Review

nVerses Capital sold out of Kiniksa Pharmaceuticals (KNSA) in Q4 2024, closing a stake of 3,200 shares — an estimated $80K sold.

nVerses Capital first reported a position in KNSA in Q3 2024 and held it in 1 quarter. The position peaked at $80K in Q3 2024. 160 funds tracked by Wall St. Rank hold KNSA as of Q4 2024.

nVerses Capital reported no remaining Kiniksa Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
nVerses Capital sold 3,200 Kiniksa Pharmaceuticals shares in Q4 2024, an estimated $80K.
nVerses Capital first reported a position in Kiniksa Pharmaceuticals in Q3 2024 and held it in 1 quarter.
nVerses Capital's Kiniksa Pharmaceuticals position peaked at $80K in Q3 2024.
160 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q4 2024.

Based on nVerses Capital's 13F filing for Q4 2024.